ストックスクリーナーアプリを入手
56.29
0.16%
-0.09
プレマーケット:
56.44
0.15
+0.27%
前日終値:
$56.38
開ける：
$56
24時間の取引高:
10.50M
Relative Volume:
1.08
時価総額：
$114.17B
収益：
$47.44B
当期純損益:
$-7.26B
株価収益率:
-15.68
EPS:
-3.59
ネットキャッシュフロー:
$13.80B
1週間 パフォーマンス:
+0.82%
1か月 パフォーマンス:
-2.36%
6か月 パフォーマンス:
+30.45%
1年 パフォーマンス:
+12.63%
1日の値動き範囲:
$55.55
$56.62
1週間の範囲:
$54.81
$56.74
52週間の値動き範囲:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.29 | 114.17B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
HB Wealth Management LLC Raises Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Trust Co. of Vermont Has $2.55 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Copy of Jim and Mia Cassady Are Bringing Pickleball Centers to Delaware County #2 - BUCKSCO.Today
Bristol-Myers Squibb Company – Consensus ‘hold’ rating and 9.1% Upside Potential - DirectorsTalk Interviews
8,382 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Decker Retirement Planning Inc. - MarketBeat
Eagle Rock Investment Company LLC Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
8,620 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Contravisory Investment Management Inc. - MarketBeat
Earnings Preview: What To Expect From Bristol-Myers Squibb's Report - Barchart
Cobenfy: Bristol Myers Squibb's Answer to Alzheimer's and SchizophreniaNews and Statistics - IndexBox, Inc.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Meyer Handelman Co. Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Radnor Capital Management LLC Has $4.57 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Acropolis Investment Management LLC Has $1.92 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for BMY - MarketBeat
Bristol Myers Says New Schizophrenia Drug Off to Strong Start - MSN
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Says New Schizophrenia Drug Off to Strong Start | Company Business News - Mint
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wright Investors Service Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management - MarketBeat
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27) - MSN
Bristol Myers Squibb CEO describes new drug for treating schizophrenia - NBC Philadelphia
Bristol-Myers Squibb (BMY) Releases New Investor Presentation - GuruFocus.com
Mid American Wealth Advisory Group Inc. Decreases Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Is Intra-Cellular Therapies Surging On Monday?Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) - Benzinga
Czech National Bank Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors - The Manila Times
Bristol Myers Squibb licenses new CAR T therapy - Investing.com
Retinoblastoma Market Profiles: Segment Size, Growth, - openPR
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
West Oak Capital LLC Has $2.28 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Franklin Street Advisors Inc. NC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Abbvie to record $3.5 bln charge related to schizophrenia drug - Reuters
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference - Benzinga
8 Undervalued Stocks That Just Raised Dividends - Morningstar
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock - Yahoo Finance
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
International Assets Investment Management LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Car T Cell Therapy Market Investment Opportunities: A Guide to 2031 | Bristol-Myers Squibb Company, Novartis - EIN News
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
114,649 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by InvesTrust - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Worth Asset Management LLC Has $583,000 Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
0.72%
大文字化:
|
ボリューム (24 時間):